AMSPARITY 40mg / 0.8ml injectible solution medication leaflet

Amsparity 40 mg/0.8 ml solution for injection

Each 0.8 ml single dose vial contains 40 mg of adalimumab.

Adalimumab is a recombinant human monoclonal antibody produced in Chinese hamster ovary cells.

Amsparity 40 mg/0.8 ml solution for injection contains 0.16 mg of polysorbate 80 in each 0.8 mlsingle dose vial, which is equivalent to 0.2 mg/ml of polysorbate 80.

For the full list of excipients, see section 6.1.

Solution for injection (injection).

Clear, colourless to very light brown solution.

Amsparity in combination with methotrexate is indicated for the treatment of active polyarticularjuvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate responseto one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given asmonotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate isinappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied inpatients aged less than 2 years.

Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of ageand older, who have had an inadequate response to, or who are intolerant of, conventional therapy (seesection 5.1).

Amsparity is indicated for the treatment of severe chronic plaque psoriasis in children and adolescentsfrom 4 years of age who have had an inadequate response to or are inappropriate candidates for topicaltherapy and phototherapies.

Adolescent hidradenitis suppurativa

Amsparity is indicated for the treatment of active moderate to severe hidradenitis suppurativa (HS)(acne inversa) in adolescents from 12 years of age with an inadequate response to conventionalsystemic HS therapy (see sections 5.1 and 5.2).

Amsparity is indicated for the treatment of moderately to severely active Crohn’s disease in paediatricpatients (from 6 years of age) who have had an inadequate response to conventional therapy includingprimary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to orhave contraindications for such therapies.

Amsparity is indicated for the treatment of moderately to severely active ulcerative colitis in paediatricpatients (from 6 years of age) who have had an inadequate response to conventional therapy includingcorticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to orhave medical contraindications for such therapies.

Paediatric uveitis

Amsparity is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patientsfrom 2 years of age who have had an inadequate response to or are intolerant to conventional therapy,or in whom conventional therapy is inappropriate.

Amsparity treatment should be initiated and supervised by specialist physicians experienced in thediagnosis and treatment of conditions for which Amsparity is indicated. Ophthalmologists are advisedto consult with an appropriate specialist before initiation of treatment with Amsparity (see section 4.4).

Patients treated with Amsparity should be given the patient reminder card.

After proper training in injection technique, patients may self-inject with Amsparity if their physiciandetermines that it is appropriate and with medical follow-up as necessary.

During treatment with Amsparity, other concomitant therapies (e.g. corticosteroids and/orimmunomodulatory agents) should be optimised.

Polyarticular juvenile idiopathic arthritis from 2 years of age

The recommended dose of Amsparity for patients with polyarticular juvenile idiopathic arthritis from2 years of age is based on body weight (Table 1). Amsparity is administered every other week viasubcutaneous injection.

Table 1. Amsparity dose for patients with polyarticular juvenile idiopathic arthritis

Patient weight Dosing regimen10 kg to < 30 kg 20 mg every other week≥ 30 kg 40 mg every other week

Available data suggest that clinical response is usually achieved within 12 weeks of treatment.

Continued therapy should be carefully reconsidered in a patient not responding within this time period.

There is no relevant use of adalimumab in patients aged less than 2 years for this indication.

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

The recommended dose of Amsparity for patients with enthesitis-related arthritis from 6 years of age isbased on body weight (Table 2). Amsparity is administered every other week via subcutaneousinjection.

Table 2. Amsparity dose for patients with enthesitis-related arthritis

Patient weight Dosing regimen15 kg to < 30 kg 20 mg every other week≥ 30 kg 40 mg every other week

Adalimumab has not been studied in patients with enthesitis-related arthritis aged less than 6 years.

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

The recommended Amsparity dose for patients with plaque psoriasis from 4 to 17 years of age is basedon body weight (Table 3). Amsparity is administered via subcutaneous injection.

Table 3. Amsparity dose for paediatric patients with plaque psoriasis

Patient weight Dosing regimen15 kg to < 30 kg Initial dose of 20 mg, followed by 20 mg givenevery other week starting one week after the initialdose≥ 30 kg Initial dose of 40 mg, followed by 40 mg givenevery other week starting one week after the initialdose

Continued therapy beyond 16 weeks should be carefully considered in a patient not responding withinthis time period.

If retreatment with Amsparity is indicated, the above guidance on dose and treatment duration shouldbe followed.

The safety of adalimumab in paediatric patients with plaque psoriasis has been assessed for a mean of13 months.

There is no relevant use of adalimumab in children aged less than 4 years for this indication.

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

There are no clinical trials with adalimumab in adolescent patients with HS.

The posology of adalimumab in these patients has been determined from pharmacokinetic modellingand simulation (see section 5.2).

The recommended Amsparity dose is 80 mg at Week 0 followed by 40 mg every other week starting at

Week 1 via subcutaneous injection.

In adolescent patients with inadequate response to Amsparity 40 mg every other week, an increase indosage to 40 mg every week or 80 mg every other week may be considered.

Antibiotics may be continued during treatment with Amsparity if necessary. It is recommended thatthe patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatmentwith Amsparity.

Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with noimprovement within this time period.

Should treatment be interrupted, Amsparity may be re-introduced as appropriate.

The benefit and risk of continued long-term treatment should be periodically evaluated (see adult datain section 5.1).

There is no relevant use of adalimumab in children aged less than 12 years in this indication.

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

The recommended dose of Amsparity for patients with Crohn’s disease from 6 to 17 years of age isbased on body weight (Table 4). Amsparity is administered via subcutaneous injection.

Table 4. Amsparity dose for paediatric patients with Crohn’s disease

Patient Induction dose Maintenance doseweight starting at week 4< 40 kg * 40 mg at Week 0 and 20 mg at Week 2 20 mg every otherweek

In case there is a need for a more rapid response to therapywith the awareness that the risk for adverse events may behigher with use of the higher induction dose, the followingdose may be used:

* 80 mg at Week 0 and 40 mg at Week 2≥ 40 kg * 80 mg at Week 0 and 40 mg at Week 2 40 mg every otherweek

In case there is a need for a more rapid response to therapywith the awareness that the risk for adverse events may behigher with use of the higher induction dose, the followingdose may be used:

* 160 mg at Week 0 and 80 mg at Week 2

Patients who experience insufficient response may benefit from an increase in dosage:

* < 40 kg: 20 mg every week

* ≥ 40 kg: 40 mg every week or 80 mg every other week

Continued therapy should be carefully considered in a subject not responding by Week 12.

There is no relevant use of adalimumab in children aged less than 6 years for this indication.

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

The recommended dose of Amsparity for patients from 6 to 17 years of age with ulcerative colitis isbased on body weight (Table 5). Amsparity is administered via subcutaneous injection.

Table 5. Amsparity dose for paediatric patients with ulcerative colitis

Patient weight Induction dose Maintenance dose startingat Week 4*< 40 kg * 80 mg at Week 0 (given as two 40 mg 40 mg every other weekinjections in one day) and

* 40 mg at Week 2 (given as one 40 mginjection)≥ 40 kg * 160 mg at Week 0 (given as four 40 mg 80 mg every other weekinjections in one day or two 40 mginjections per day for two consecutivedays) and

* 80 mg at Week 2 (given as two 40 mginjections in one day)

* Paediatric patients who turn 18 years of age while on Amsparity should continue their prescribedmaintenance dose.

Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs ofresponse within this time period.

There is no relevant use of adalimumab in children aged less than 6 years in this indication.

Amsparity may be available in different strengths and/or presentations depending on the individualtreatment needs.

Paediatric uveitis

The recommended dose of Amsparity for paediatric patients with uveitis from 2 years of age is basedon body weight (Table 6). Amsparity is administered via subcutaneous injection.

In paediatric uveitis, there is no experience in the treatment with adalimumab without concomitanttreatment with methotrexate.

Table 6. Amsparity dose for paediatric patients with uveitis

Patient weight Dosing regimen< 30 kg 20 mg every other week in combination withmethotrexate≥ 30 kg 40 mg every other week in combination withmethotrexate

When Amsparity therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg forpatients ≥ 30 kg may be administered one week prior to the start of maintenance therapy. No clinicaldata are available on the use of an Amsparity loading dose in children < 6 years of age (seesection 5.2).

There is no relevant use of adalimumab in children aged less than 2 years in this indication.

It is recommended that the benefit and risk of continued long-term treatment should be evaluated on ayearly basis (see section 5.1).

Amsparity may be available in other strengths and/or presentations depending on the individualtreatment needs.

Adalimumab has not been studied in these patient populations. No dose recommendations can bemade.

Amsparity is administered by subcutaneous injection. Full instructions for use are provided in thepackage leaflet.

Amsparity is available in other strengths and presentations.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (seesection 4.4).

Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).

In order to improve the traceability of biological medicinal products, the name and the batch numberof the administered product should be clearly recorded.

Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung functionmay increase the risk for developing infections. Patients must therefore be monitored closely forinfections, including tuberculosis, before, during and after treatment with Amsparity. Because theelimination of adalimumab may take up to four months, monitoring should be continued throughoutthis period.

Treatment with Amsparity should not be initiated in patients with active infections including chronicor localised infections until infections are controlled. In patients who have been exposed totuberculosis and patients who have travelled in areas of high risk of tuberculosis or endemic mycoses,such as histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with

Amsparity should be considered prior to initiating therapy (see Other opportunistic infections).

Patients who develop a new infection while undergoing treatment with Amsparity should be monitoredclosely and undergo a complete diagnostic evaluation. Administration of Amsparity should bediscontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial orantifungal therapy should be initiated until the infection is controlled. Physicians should exercisecaution when considering the use of Amsparity in patients with a history of recurring infection or withunderlying conditions which may predispose patients to infections, including the use of concomitantimmunosuppressive medications.

Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, orother opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported inpatients receiving adalimumab.

Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis andsepticaemia. Hospitalisation or fatal outcomes associated with infections have been reported.

Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patientsreceiving adalimumab. Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated)tuberculosis.

Before initiation of therapy with Amsparity, all patients must be evaluated for both active or inactive(“latent”) tuberculosis infection. This evaluation should include a detailed medical assessment ofpatient history of tuberculosis or possible previous exposure to people with active tuberculosis andprevious and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skintest and chest X-ray) should be performed in all patients (local recommendations may apply). It isrecommended that the conduct and results of these tests are recorded in the patient reminder card.

Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patientswho are severely ill or immunocompromised.

If active tuberculosis is diagnosed, Amsparity therapy must not be initiated (see section 4.3).

In all situations described below, the benefit/risk balance of therapy should be very carefullyconsidered.

If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should beconsulted.

If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosisprophylaxis treatment before the initiation of Amsparity, and in accordance with localrecommendations.

Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of

Amsparity in patients with several or significant risk factors for tuberculosis despite a negative test fortuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequatecourse of treatment cannot be confirmed.

Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred inpatients treated with adalimumab. Some patients who have been successfully treated for activetuberculosis have redeveloped tuberculosis while being treated with adalimumab.

Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosisinfection (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) occur during orafter therapy with Amsparity.

Opportunistic infections, including invasive fungal infections have been observed in patients receivingadalimumab. These infections have not consistently been recognised in patients taking

TNF-antagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fataloutcomes.

For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitantshock an invasive fungal infection should be suspected and administration of Amsparity should bepromptly discontinued. Diagnosis and administration of empiric antifungal therapy in these patientsshould be made in consultation with a physician with expertise in the care of patients with invasivefungal infections.

Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including adalimumab,who are chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fataloutcome. Patients should be tested for HBV infection before initiating treatment with Amsparity. Forpatients who test positive for hepatitis B infection, consultation with a physician with expertise in thetreatment of hepatitis B is recommended.

Carriers of HBV who require treatment with Amsparity should be closely monitored for signs andsymptoms of active HBV infection throughout therapy and for several months following terminationof therapy. Adequate data from treating patients who are carriers of HBV with anti-viral therapy inconjunction with TNF-antagonist therapy to prevent HBV reactivation are not available. In patientswho develop HBV reactivation, Amsparity should be stopped and effective anti-viral therapy withappropriate supportive treatment should be initiated.

TNF-antagonists including adalimumab have been associated in rare instances with new onset orexacerbation of clinical symptoms and/or radiographic evidence of central nervous systemdemyelinating disease including multiple sclerosis and optic neuritis, and peripheral demyelinatingdisease, including Guillain-Barré syndrome. Prescribers should exercise caution in considering the useof Amsparity in patients with pre-existing or recent-onset central or peripheral nervous systemdemyelinating disorders; discontinuation of Amsparity should be considered if any of these disordersdevelop. There is a known association between intermediate uveitis and central demyelinatingdisorders. Neurologic evaluation should be performed in patients with non-infectious intermediateuveitis prior to the initiation of Amsparity therapy and regularly during treatment to assess forpre-existing or developing central demyelinating disorders.

Serious allergic reactions associated with adalimumab were rare during clinical trials. Non-seriousallergic reactions associated with adalimumab were uncommon during clinical trials. Reports ofserious allergic reactions including anaphylaxis have been received following adalimumabadministration. If an anaphylactic reaction or other serious allergic reaction occurs, administration of

Amsparity should be discontinued immediately and appropriate therapy initiated.

In a study of 64 patients with rheumatoid arthritis that were treated with adalimumab, there was noevidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, orchange in enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.

In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies includinglymphoma have been observed among patients receiving a TNF-antagonist compared with controlpatients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia havebeen reported in patients treated with a TNF-antagonist. There is an increased background risk forlymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active,inflammatory disease, which complicates the risk estimation. With the current knowledge, a possiblerisk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a

TNF-antagonist cannot be excluded.

Malignancies, some fatal, have been reported among children, adolescents and young adults (up to22 years of age) treated with TNF-antagonists (initiation of therapy ≤ 18 years of age), includingadalimumab in the post marketing setting. Approximately half the cases were lymphomas. The othercases represented a variety of different malignancies and included rare malignancies usually associatedwith immunosuppression. A risk for the development of malignancies in children and adolescentstreated with TNF-antagonists cannot be excluded.

Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treatedwith adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and isusually fatal. Some of these hepatosplenic T-cell lymphomas with adalimumab have occurred in youngadult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatorybowel disease. The potential risk with the combination of azathioprine or 6-mercaptopurine andadalimumab should be carefully considered. A risk for the development of hepatosplenic T-celllymphoma in patients treated with Amsparity cannot be excluded (see section 4.8).

No studies have been conducted that include patients with a history of malignancy or in whomtreatment with adalimumab is continued following development of malignancy. Thus, additionalcaution should be exercised in considering adalimumab treatment of these patients (see section 4.8).

All patients, and in particular patients with a medical history of extensive immunosuppressant therapyor psoriasis patients with a history of PUVA treatment should be examined for the presence ofnon-melanoma skin cancer prior to and during treatment with Amsparity. Melanoma and Merkel cellcarcinoma have also been reported in patients treated with TNF-antagonists including adalimumab(see section 4.8).

In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patientswith moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly inthe lung or head and neck, were reported in infliximab-treated patients compared with control patients.

All patients had a history of heavy smoking. Therefore, caution should be exercised when using any

TNF-antagonist in COPD patients, as well as in patients with increased risk for malignancy due toheavy smoking.

With current data it is not known if adalimumab treatment influences the risk for developing dysplasiaor colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or coloncarcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosingcholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened fordysplasia at regular intervals before therapy and throughout their disease course. This evaluationshould include colonoscopy and biopsies per local recommendations.

Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.

Adverse events of the haematologic system, including medically significant cytopenia (e.g.

thrombocytopenia, leukopenia) have been reported with adalimumab. All patients should be advised toseek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias(e.g. persistent fever, bruising, bleeding, pallor) while on Amsparity. Discontinuation of Amsparitytherapy should be considered in patients with confirmed significant haematologic abnormalities.

Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalentvirus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who weretreated with adalimumab or placebo. No data are available on the secondary transmission of infectionby live vaccines in patients receiving adalimumab.

It is recommended that paediatric patients, if possible, be brought up to date with all immunisations inagreement with current immunisation guidelines prior to initiating adalimumab therapy.

Patients on adalimumab may receive concurrent vaccinations, except for live vaccines. Administrationof live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for5 months following the mother’s last adalimumab injection during pregnancy.

In a clinical trial with another TNF-antagonist worsening congestive heart failure and increasedmortality due to congestive heart failure have been observed. Cases of worsening congestive heartfailure have also been reported in patients receiving adalimumab. Amsparity should be used withcaution in patients with mild heart failure (NYHA class I/II). Amsparity is contraindicated in moderateto severe heart failure (see section 4.3). Treatment with Amsparity must be discontinued in patientswho develop new or worsening symptoms of congestive heart failure.

Treatment with Amsparity may result in the formation of autoimmune antibodies. The impact oflong-term treatment with adalimumab on the development of autoimmune diseases is unknown. If apatient develops symptoms suggestive of a lupus-like syndrome following treatment with Amsparityand is positive for antibodies against double-stranded DNA, further treatment with Amsparity shouldnot be given (see section 4.8).

Concurrent administration of biologic DMARDS or TNF-antagonists

Serious infections were seen in clinical studies with concurrent use of anakinra and another

TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because ofthe nature of the adverse events seen with the combination of etanercept and anakinra therapy, similartoxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, thecombination of adalimumab and anakinra is not recommended (see section 4.5).

Concomitant administration of adalimumab with other biologic DMARDS (e.g. anakinra andabatacept) or other TNF-antagonists is not recommended based upon the possible increased risk forinfections, including serious infections and other potential pharmacological interactions (seesection 4.5).

There is limited safety experience of surgical procedures in patients treated with adalimumab. Thelong half-life of adalimumab should be taken into consideration if a surgical procedure is planned. Apatient who requires surgery while on Amsparity should be closely monitored for infections, andappropriate actions should be taken. There is limited safety experience in patients undergoingarthroplasty while receiving adalimumab.

Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricturethat may require surgical treatment. Available data suggest that adalimumab does not worsen or causestrictures.

The frequency of serious infections among adalimumab-treated subjects over 65 years of age (3.7%)was higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particularattention regarding the risk for infection should be paid when treating the elderly.

See vaccinations above.

Polysorbate

This medicinal product contains polysorbate 80. Amsparity 40 mg/0.8 ml solution for injectioncontains 0.16 mg of polysorbate 80 in each 0.8 ml single dose vial, which is equivalent to 0.2 mg/ml ofpolysorbate 80. Polysorbate 80 may cause hypersensitivity reactions.

This medicinal product contains less than 1 mmol of sodium (23 mg) per 0.8 ml dose, i.e. essentially‘sodium-free’.

Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis andpsoriatic arthritis patients taking adalimumab as monotherapy and those taking concomitantmethotrexate. Antibody formation was lower when adalimumab was given together with methotrexatein comparison with use as monotherapy. Administration of adalimumab without methotrexate resultedin increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (seesection 5.1).

The combination of Amsparity and anakinra is not recommended (see section 4.4 “Concurrentadministration of biologic DMARDS or TNF-antagonists”).

The combination of Amsparity and abatacept is not recommended (see section 4.4 “Concurrentadministration of biologic DMARDS or TNF-antagonists”).

Women of childbearing potential should consider the use of adequate contraception to preventpregnancy and continue its use for at least five months after the last Amsparity treatment.

A large number (approximately 2,100) of prospectively collected pregnancies exposed to adalimumabresulting in live birth with known outcomes, including more than 1,500 exposed during the firsttrimester, does not indicate an increase in the rate of malformation in the newborn.

In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn’s disease (CD)treated with adalimumab at least during the first trimester and 120 women with RA or CD not treatedwith adalimumab were enrolled. The primary endpoint was the birth prevalence of major birth defects.

The rate of pregnancies ending with at least one live born infant with a major birth defect was6/69 (8.7%) in the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with

RA (unadjusted OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated womenwith CD and 3/32 (9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16).

The adjusted OR (accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CDcombined. There were no distinct differences between adalimumab-treated and untreated women forthe secondary endpoints spontaneous abortions, minor birth defects, preterm delivery, birth size andserious or opportunistic infections and no stillbirths or malignancies were reported. The interpretationof data may be impacted due to methodological limitations of the study, including small sample sizeand non-randomised design.

In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity,embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available(see section 5.3).

Due to its inhibition of TNFα, adalimumab administered during pregnancy could affect normalimmune responses in the newborn. Adalimumab should only be used during pregnancy if clearlyneeded.

Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumabduring pregnancy. Consequently, these infants may be at increased risk for infection. Administrationof live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for5 months following the mother’s last adalimumab injection during pregnancy.

Limited information from the published literature indicates that adalimumab is excreted in breast milkat very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1%to 1% of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinalproteolysis and have poor bioavailability. No effects on the breastfed newborns/infants are anticipated.

Consequently, Amsparity can be used during breast-feeding.

Preclinical data on fertility effects of adalimumab are not available.

Adalimumab may have a minor influence on the ability to drive and use machines. Vertigo and visualimpairment may occur following administration of Amsparity (see section 4.8).

Adalimumab was studied in 9,506 patients in pivotal controlled and open-label trials for up to60 months or more. These trials included rheumatoid arthritis patients with short term and longstanding disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis andenthesitis-related arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axialspondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerativecolitis, psoriasis, hidradenitis suppurativa and uveitis patients. The pivotal controlled studies involved6,089 patients receiving adalimumab and 3,801 patients receiving placebo or active comparator duringthe controlled period.

The proportion of patients who discontinued treatment due to adverse events during the double-blind,controlled portion of pivotal studies was 5.9% for patients taking adalimumab and 5.4% for controltreated patients.

The most commonly reported adverse reactions are infections (such as nasopharyngitis, upperrespiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, painor swelling), headache and musculoskeletal pain.

Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumabaffect the immune system and their use may affect the body’s defence against infection and cancer.

Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBVreactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also beenreported with use of adalimumab.

Serious haematological, neurological and autoimmune reactions have also been reported. Theseinclude rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events andreports of lupus, lupus-related conditions and Stevens-Johnson syndrome.

In general, the adverse events in paediatric patients were similar in frequency and type to those seen inadult patients.

The following list of adverse reactions is based on experience from clinical trials and on postmarketingexperience and are displayed by system organ class and frequency in Table 7 below: very common(≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to< 1/1,000); and not known (cannot be estimated from the available data). Within each frequencygrouping, undesirable effects are presented in order of decreasing seriousness. The highest frequencyseen among the various indications has been included. An asterisk (*) appears in the SOC column iffurther information is found elsewhere in sections pct. 4.3, pct. 4.4 and 4.8.

Table 7. Undesirable effects

System organ class Frequency Adverse reaction

Infections and infestations* Very common Respiratory tract infections (including lowerand upper respiratory tract infection,pneumonia, sinusitis, pharyngitis,nasopharyngitis and pneumonia herpes viral)

Common Systemic infections (including sepsis,candidiasis and influenza),intestinal infections (includinggastroenteritis viral),skin and soft tissue infections (includingparonychia, cellulitis, impetigo, necrotisingfasciitis and herpes zoster),ear infections,oral infections (including herpes simplex,oral herpes and tooth infections),reproductive tract infections (includingvulvovaginal mycotic infection),urinary tract infections (includingpyelonephritis),fungal infections,joint infections

Uncommon Neurological infections (including viralmeningitis),opportunistic infections and tuberculosis(including coccidioidomycosis,histoplasmosis and mycobacterium aviumcomplex infection),bacterial infections,eye infections,diverticulitis1

System organ class Frequency Adverse reaction

Neoplasms benign, malignant Common Skin cancer excluding melanoma (includingand unspecified (including basal cell carcinoma and squamous cellcysts and polyps)* carcinoma),benign neoplasm

Uncommon Lymphoma**,solid organ neoplasm (including breastcancer, lung neoplasm and thyroidneoplasm),melanoma**

Rare Leukaemia1

Not known Hepatosplenic T-cell lymphoma1,

Merkel cell carcinoma (neuroendocrinecarcinoma of the skin)1,

Kaposi’s sarcoma

Blood and the lymphatic Very common Leukopenia (including neutropenia andsystem disorders* agranulocytosis),anaemia

Common Leucocytosis,thrombocytopenia

Uncommon Idiopathic thrombocytopenic purpura

Rare Pancytopenia

Immune system disorders* Common Hypersensitivity,allergies (including seasonal allergy)

Uncommon Sarcoidosis1,vasculitis

Rare Anaphylaxis1

Metabolism and nutrition Very common Lipids increaseddisorders

Common Hypokalaemia,uric acid increased,blood sodium abnormal,hypocalcaemia,hyperglycaemia,hypophosphatemia,dehydration

Psychiatric disorders Common Mood alterations (including depression),anxiety,insomnia

Nervous system disorders* Very common Headache

System organ class Frequency Adverse reaction

Common Paraesthesias (including hypoesthesia),migraine,nerve root compression

Uncommon Cerebrovascular accident1,tremor,neuropathy

Rare Multiple sclerosis,demyelinating disorders (e.g. optic neuritis,

Guillain-Barré syndrome)1

Eye disorders Common Visual impairment,conjunctivitis,blepharitis,eye swelling

Uncommon Diplopia

Ear and labyrinth disorders Common Vertigo

Uncommon Deafnesstinnitus

Cardiac disorders* Common Tachycardia

Uncommon Myocardial infarction1,arrhythmia,congestive heart failure

Rare Cardiac arrest

Vascular disorders Common Hypertension,flushing,haematoma

Uncommon Aortic aneurysm,vascular arterial occlusion,thrombophlebitis

Respiratory, thoracic and Common Asthma,mediastinal disorders* dyspnoea,cough

Uncommon Pulmonary embolism1,interstitial lung disease,chronic obstructive pulmonary disease,pneumonitis,pleural effusion1

Rare Pulmonary fibrosis1

Gastrointestinal disorders Very common Abdominal pain,nausea and vomiting

System organ class Frequency Adverse reaction

Common GI haemorrhage,dyspepsia,gastroesophageal reflux disease,sicca syndrome

Uncommon Pancreatitis,dysphagia,face oedema

Rare Intestinal perforation1

Hepato-biliary disorders* Very common Elevated liver enzymes

Uncommon Cholecystitis and cholelithiasis,hepatic steatosis,bilirubin increased

Rare Hepatitisreactivation of hepatitis B1autoimmune hepatitis1

Not known Liver failure1

Skin and subcutaneous tissue Very common Rash (including exfoliative rash)disorders

Common Worsening or new onset of psoriasis(including palmoplantar pustular psoriasis)1,urticaria,bruising (including purpura),dermatitis (including eczema),onychoclasis,hyperhidrosis,alopecia1,pruritus

Uncommon Night sweats,scar

Rare Erythema multiforme1,

Stevens-Johnson syndrome1,angioedema1,cutaneous vasculitis1,lichenoid skin reaction1

Not known Worsening of symptoms ofdermatomyositis1

Musculoskeletal and Very common Musculoskeletal painconnective tissue disorders

Common Muscle spasms (including blood creatinephosphokinase increased)

Uncommon Rhabdomyolysis,systemic lupus erythematosus

System organ class Frequency Adverse reaction

Rare Lupus-like syndrome1

Renal and urinary disorders Common Renal impairment,haematuria

Uncommon Nocturia

Reproductive system and Uncommon Erectile dysfunctionbreast disorders

General disorders and Very common Injection site reaction (including injectionadministration site site erythema)conditions*

Common Chest pain,oedema,pyrexia1

Uncommon Inflammation

Investigations* Common Coagulation and bleeding disorders(including activated partial thromboplastintime prolonged),autoantibody test positive (includingdouble-stranded DNA antibody),blood lactate dehydrogenase increased

Not known Weight increased2

Injury, poisoning and Common Impaired healingprocedural complications

* further information is found elsewhere in sections pct. 4.3, pct. 4.4 and 4.8

** including open-label extension studies1 including spontaneous reporting data2 The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adultindications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months.

Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures ofapproximately 1-2 years without control group, particularly in patients with Crohn’s disease andulcerative colitis. The mechanism behind this effect is unclear but could be associated with the anti-inflammatory effect of adalimumab.

The safety profile for patients with HS treated with adalimumab weekly was consistent with the knownsafety profile of adalimumab.

The safety profile for patients with uveitis treated with adalimumab every other week was consistentwith the known safety profile of adalimumab.

In the pivotal controlled trials in adults and children, 12.9% of patients treated with adalimumabdeveloped injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), comparedto 7.2% of patients receiving placebo or active control. Injection site reactions generally did notnecessitate discontinuation of the medicinal product.

In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year inthe adalimumab-treated patients and 1.46 per patient year in the placebo and active control-treatedpatients. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, andsinusitis. Most patients continued on adalimumab after the infection resolved.

The incidence of serious infections was 0.04 per patient year in adalimumab-treated patients and0.03 per patient year in placebo and active control-treated patients.

In controlled and open-label adult and paediatric studies with adalimumab, serious infections(including fatal infections, which occurred rarely) have been reported, which include reports oftuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections(e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis,pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurredwithin the first eight months after initiation of therapy and may reflect recrudescence of latent disease.

No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient-yearsduring adalimumab trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathicarthritis and enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatricpatients with an exposure of 498.1 patient-years during adalimumab trials in paediatric patients with

Crohn’s disease. No malignancies were observed in 77 paediatric patients with an exposure of80.0 patient-years during an adalimumab trial in paediatric patients with chronic plaque psoriasis. Nomalignancies were observed in 93 paediatric patients with an exposure of 65.3 patient years during anadalimumab trial in paediatric patients with ulcerative colitis. No malignancies were observed in60 paediatric patients with an exposure of 58.4 patient-years during an adalimumab trial in paediatricpatients with uveitis.

During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration inpatients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axialspondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitissuppurativa, Crohn’s disease, ulcerative colitis and uveitis, malignancies, other than lymphoma andnon-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per1,000 patient-years among 5,291 adalimumab-treated patients versus a rate of 6.3 (3.4, 11.8) per1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months foradalimumab and 3.8 months for control-treated patients). The rate (95% confidence interval) ofnon-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among adalimumab-treatedpatients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients. Of these skin cancers,squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7 (1.4, 5.4) per1,000 patient-years among adalimumab-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-yearsamong control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per1,000 patient-years among adalimumab-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-yearsamong control patients.

When combining controlled portions of these trials and ongoing and completed open-label extensionstudies with a median duration of approximately 3.3 years including 6,427 patients and over26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma andnon-melanoma skin cancers is approximately 8.5 per 1,000 patient-years. The observed rate ofnon-melanoma skin cancers is approximately 9.6 per 1,000 patient-years, and the observed rate oflymphomas is approximately 1.3 per 1,000 patient-years.

In post-marketing experience from January 2003 to December 2010, predominantly in patients withrheumatoid arthritis, the spontaneously reported rate of malignancies is approximately 2.7 per1,000 patient treatment years. The spontaneously reported rates for non-melanoma skin cancers andlymphomas are approximately 0.2 and 0.3 per 1,000 patient treatment years, respectively (seesection 4.4).

Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treatedwith adalimumab (see section 4.4).

Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritisstudies I − V. In these trials, 11.9% of patients treated with adalimumab and 8.1% of placebo andactive control − treated patients that had negative baseline anti-nuclear antibody titres reported positivetitres at Week 24. Two patients out of 3,441 treated with adalimumab in all rheumatoid arthritis andpsoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome. Thepatients improved following discontinuation of therapy. No patients developed lupus nephritis orcentral nervous system symptoms.

In controlled Phase 3 trials of adalimumab in patients with rheumatoid arthritis and psoriatic arthritiswith a control period duration ranging from 4 to 104 weeks, ALT elevations ≥ 3 x ULN occurred in3.7% of adalimumab-treated patients and 1.6% of control-treated patients.

In controlled Phase 3 trials of adalimumab in patients with polyarticular juvenile idiopathic arthritiswho were 4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations≥ 3 x ULN occurred in 6.1% of adalimumab-treated patients and 1.3% of control-treated patients.

Most ALT elevations occurred with concomitant methotrexate use. No ALT elevations ≥ 3 x ULNoccurred in the Phase 3 trial of adalimumab in patients with polyarticular juvenile idiopathic arthritiswho were 2 to < 4 years.

In controlled Phase 3 trials of adalimumab in patients with Crohn’s disease and ulcerative colitis witha control period ranging from 4 to 52 weeks, ALT elevations ≥ 3 x ULN occurred in 0.9% ofadalimumab-treated patients and 0.9% of controlled-treated patients.

In the Phase 3 trial of adalimumab in patients with paediatric Crohn’s disease which evaluated efficacyand safety of two body weight adjusted maintenance dose regimens following body weight adjustedinduction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6% (5/192) ofpatients of whom 4 were receiving concomitant immunosuppressants at baseline.

In controlled Phase 3 trials of adalimumab in patients with plaque psoriasis with a control periodduration ranging from 12 to 24 weeks, ALT elevations ≥ 3 x ULN occurred in 1.8% ofadalimumab-treated patients and 1.8% of control-treated patients.

No ALT elevations ≥ 3 x ULN occurred in the Phase 3 trial of adalimumab in paediatric patients withplaque psoriasis.

In controlled trials of adalimumab (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followedby 40 mg every week starting at Week 4), in patients with hidradenitis suppurativa with a controlperiod duration ranging from 12 to 16 weeks, ALT elevations ≥ 3 x ULN occurred in 0.3% ofadalimumab-treated patients and 0.6% of control-treated patients.

In controlled trials of adalimumab (initial doses of 80 mg at Week 0 followed by 40 mg every otherweek starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of166.5 days and 105.0 days in adalimumab-treated and control-treated patients, respectively, ALTelevations ≥ 3 x ULN occurred in 2.4% of adalimumab-treated patients and 2.4% of control-treatedpatients.

In the controlled Phase 3 trial of adalimumab in patients with paediatric ulcerative colitis (N = 93)which evaluated efficacy and safety of a maintenance dose of 0.6 mg/kg (maximum of 40 mg) everyother week (N = 31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every week (N = 32),following body weight adjusted induction dosing of 2.4 mg/kg (maximum of 160 mg) at Week 0 and

Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N = 63), or an induction dose of 2.4 mg/kg(maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2(N = 30), ALT elevations ≥ 3 x ULN occurred in 1.1% (1/93) of patients.

Across all indications in clinical trials patients with raised ALT were asymptomatic and in most caseselevations were transient and resolved on continued treatment. However, there have also beenpost-marketing reports of liver failure as well as less severe liver disorders that may precede liverfailure, such as hepatitis including autoimmune hepatitis in patients receiving adalimumab.

In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverseevents were seen with the combination of adalimumab and azathioprine/6-mercaptopurine comparedwith adalimumab alone.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Itallows continued monitoring of the benefit/risk balance of the medicinal product. Healthcareprofessionals are asked to report any suspected adverse reactions via the national reporting systemlisted in Appendix V.

No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated hasbeen multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose.

Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.

ATC code: L04AB04

Amsparity is a biosimilar medicinal product. Detailed information is available on the website of the

European Medicines Agency https://www.ema.europa.eu.

Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking itsinteraction with the p55 and p75 cell surface TNF receptors.

Adalimumab also modulates biological responses that are induced or regulated by TNF, includingchanges in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1,and ICAM-1 with an IC50 of 0.1-0.2 nM).

After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) wasobserved, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrixmetalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilagedestruction were also decreased after adalimumab administration. Patients treated with adalimumabusually experienced improvement in haematological signs of chronic inflammation.

A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathicarthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment withadalimumab. In patients with Crohn’s disease, a reduction of the number of cells expressinginflammatory markers in the colon including a significant reduction of expression of TNFα was seen.

Endoscopic studies in intestinal mucosa have shown evidence of mucosal healing inadalimumab-treated patients.

Adults with rheumatoid arthritis

Adalimumab was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. Theefficacy and safety of adalimumab were assessed in five randomised, double-blind and well-controlledstudies. Some patients were treated for up to 120 months duration.

RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were≥ 18 years old, had failed therapy with at least one disease-modifying, anti-rheumatic drug and hadinsufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant)every week and whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20,40 or 80 mg of adalimumab or placebo were given every other week for 24 weeks.

RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were≥ 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Dosesof 20 or 40 mg of adalimumab were given by subcutaneous injection every other week with placebo onalternative weeks or every week for 26 weeks; placebo was given every week for the same duration.

No other disease-modifying anti-rheumatic drugs were allowed.

RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were≥ 18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or havebeen intolerant to 10 mg of methotrexate every week. There were three groups in this study. The firstreceived placebo injections every week for 52 weeks. The second received 20 mg of adalimumabevery week for 52 weeks. The third group received 40 mg of adalimumab every other week withplacebo injections on alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled inan open-label extension phase in which 40 mg of adalimumab/MTX was administered every otherweek up to 10 years.

RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoidarthritis who were ≥ 18 years old. Patients were permitted to be either disease-modifying,anti-rheumatic drug-naïve or to remain on their pre-existing rheumatologic therapy provided thattherapy was stable for a minimum of 28 days. These therapies include methotrexate, leflunomide,hydroxychloroquine, sulfasalazine and/or gold salts. Patients were randomised to 40 mg ofadalimumab or placebo every other week for 24 weeks.

RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active earlyrheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy ofadalimumab 40 mg every other week/methotrexate combination therapy, adalimumab 40 mg everyother week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rateof progression of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first104 weeks, 497 patients enrolled in an open-label extension phase in which 40 mg of adalimumab wasadministered every other week up to 10 years.

The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was thepercent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RAstudy V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and

V had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by

X-ray results). RA study III also had a primary endpoint of changes in quality of life.

The percent of adalimumab-treated patients achieving ACR 20, 50 and 70 responses was consistentacross RA studies I, II and III. The results for the 40 mg every other week dose are summarised in

Table 8.

Table 8. ACR responses in placebo-controlled trials (percent of patients)

Response RA Study Ia** RA Study IIa** RA Study IIIa**

Placebo/ Adalimumab Adalimumab Placebo/ Adalimumabb

MTXc b c Placebo/ MTX b MTXc/MTXcn = 110n = 60 n = 63 n = 113 n = 200 n = 207

ACR 206 months 13.3% 65.1% 19.1% 46.0% 29.5% 63.3%12 months NA NA NA NA 24.0% 58.9%

ACR 506 months 6.7% 52.4% 8.2% 22.1% 9.5% 39.1%12 months NA NA NA NA 9.5% 41.5%

ACR 706 months 3.3% 23.8% 1.8% 12.4% 2.5% 20.8%12 months NA NA NA NA 4.5% 23.2%a RA study I at 24 weeks, RA study II at 26 weeks, and RA study III at 24 and 52 weeksb 40 mg adalimumab administered every other weekc MTX = methotrexate

** p < 0.01, adalimumab versus placebo

In RA studies I-IV, all individual components of the ACR response criteria (number of tender andswollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ)scores and CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III,these improvements were maintained throughout 52 weeks.

In the open-label extension for RA study III, most patients who were ACR responders maintainedresponse when followed for up to 10 years. Of 207 patients who were randomised to adalimumab40 mg every other week, 114 patients continued on adalimumab 40 mg every other week for 5 years.

Among those, 86 patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses;and 41 patients (36%) had ACR 70 responses. Of 207 patients, 81 patients continued on adalimumab40 mg every other week for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses;56 patients (69.1%) had ACR 50 responses; and 43 patients (53.1%) had ACR 70 responses.

In RA study IV, the ACR 20 response of patients treated with adalimumab plus standard of care wasstatistically significantly better than patients treated with placebo plus standard of care (p < 0.001).

In RA studies I-IV, adalimumab-treated patients achieved statistically significant ACR 20 and50 responses compared to placebo as early as one to two weeks after initiation of treatment.

In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combinationtherapy with adalimumab and methotrexate led to faster and significantly greater ACR responses thanmethotrexate monotherapy and adalimumab monotherapy at Week 52 and responses were sustained at

Week 104 (see Table 9).

Table 9. ACR responses in RA study V (percent of patients)

MTX Adalimumab Adalimumab/MTX

Response p-valuea p-valueb p-valuecn = 257 n = 274 n = 268

ACR 20

Week 52 62.6% 54.4% 72.8% 0.013 < 0.001 0.043

Week 104 56.0% 49.3% 69.4% 0.002 < 0.001 0.140

ACR 50

Week 52 45.9% 41.2% 61.6% < 0.001 < 0.001 0.317

Week 104 42.8% 36.9% 59.0% < 0.001 < 0.001 0.162

ACR 70

Week 52 27.2% 25.9% 45.5% < 0.001 < 0.001 0.656

Week 104 28.4% 28.1% 46.6% < 0.001 < 0.001 0.864a p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexatecombination therapy using the Mann-Whitney U test.b p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combinationtherapy using the Mann-Whitney U test.c p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the

Mann-Whitney U test.

In the open-label extension for RA study V, ACR response rates were maintained when followed forup to 10 years. Of 542 patients who were randomised to adalimumab 40 mg every other week,170 patients continued on adalimumab 40 mg every other week for 10 years. Among those,154 patients (90.6%) had ACR 20 responses; 127 patients (74.7%) had ACR 50 responses; and102 patients (60.0%) had ACR 70 responses.

At Week 52, 42.9% of patients who received adalimumab/methotrexate combination therapy achievedclinical remission (DAS28 (CRP) < 2.6) compared to 20.6% of patients receiving methotrexatemonotherapy and 23.4% of patients receiving adalimumab monotherapy. adalimumab/methotrexatecombination therapy was clinically and statistically superior to methotrexate (p < 0.001) andadalimumab monotherapy (p < 0.001) in achieving a low disease state in patients with recentlydiagnosed moderate to severe rheumatoid arthritis. The response for the two monotherapy arms wassimilar (p = 0.447). Of 342 subjects originally randomised to adalimumab monotherapy oradalimumab/methotrexate combination therapy who entered the open-label extension study,171 subjects completed 10 years of adalimumab treatment. Among those, 109 subjects (63.7%) werereported to be in remission at 10 years.

In RA study III, where adalimumab-treated patients had a mean duration of rheumatoid arthritis ofapproximately 11 years, structural joint damage was assessed radiographically and expressed aschange in modified Total Sharp Score (TSS) and its components, the erosion score and joint spacenarrowing score. Adalimumab/methotrexate patients demonstrated significantly less radiographicprogression than patients receiving methotrexate alone at 6 and 12 months (see Table 10).

In the open-label extension of RA Study III, the reduction in rate of progression of structural damageis maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treatedwith 40 mg adalimumab every other week were evaluated radiographically. Among those, 48 patientsshowed no progression of structural damage defined by a change from baseline in the mTSS of 0.5 orless. At 10 years, 79 of 207 patients originally treated with 40 mg adalimumab every other week wereevaluated radiographically. Among those, 40 patients showed no progression of structural damagedefined by a change from baseline in the mTSS of 0.5 or less.

Table 10. Radiographic mean changes over 12 months in RA study III

Placebo/ Adalimumab/MTX Placebo/MTX- Adalim p-value

MTXa 40 mg every other umab/MTX (95%week confidence intervalb)

Total Sharp Score 2.7 0.1 2.6 (1.4, 3.8) < 0.001c

Erosion score 1.6 0.0 1.6 (0.9, 2.2) < 0.001

JSNd score 1.0 0.1 0.9 (0.3, 1.4) 0.002a methotrexateb 95% confidence intervals for the differences in change scores between methotrexate and adalimumab.c Based on rank analysisd Joint Space Narrowing

In RA study V, structural joint damage was assessed radiographically and expressed as change inmodified Total Sharp Score (see Table 11).

Table 11. Radiographic mean changes at Week 52 in RA study V

Adalimumab/

MTX Adalimumab

MTXn = 257 n = 274n = 268(95% (95% p-valuea p-valueb p-valuec(95%confidence confidenceconfidenceinterval) interval)interval)

Total Sharp5.7 (4.2-7.3) 3.0 (1.7-4.3) 1.3 (0.5-2.1) < 0.001 0.0020 < 0.001

Score

Erosion3.7 (2.7-4.7) 1.7 (1.0-2.4) 0.8 (0.4-1.2) < 0.001 0.0082 < 0.001score

JSN score 2.0 (1.2-2.8) 1.3 (0.5-2.1) 0.5 (0-1.0) < 0.001 0.0037 0.151a p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexatecombination therapy using the Mann-Whitney U test.b p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexatecombination therapy using the Mann-Whitney U test.c p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapyusing the Mann-Whitney U test.

Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression(change from baseline in modified Total Sharp Score ≤ 0.5) was significantly higher withadalimumab/methotrexate combination therapy (63.8% and 61.2%, respectively) compared tomethotrexate monotherapy (37.4% and 33.5% respectively, p < 0.001) and adalimumab monotherapy(50.7%, p < 0.002 and 44.5%, p < 0.001, respectively).

In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified

Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomised to methotrexatemonotherapy, adalimumab monotherapy and adalimumab/methotrexate combination therapy,respectively. The corresponding proportions of patients with no radiographic progression were 31.3%,23.7% and 36.7% respectively.

Health-related quality of life and physical function were assessed using the disability index of the

Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials,which was a pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules ofadalimumab in all four studies showed statistically significantly greater improvement in the disabilityindex of the HAQ from baseline to Month 6 compared to placebo and in RA study III the same wasseen at Week 52. Results from the Short Form Health Survey (SF-36) for all doses/schedules ofadalimumab in all four studies support these findings, with statistically significant physical componentsummary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40 mgevery other week dose. A statistically significant decrease in fatigue as measured by functionalassessment of chronic illness therapy (FACIT) scores was seen in all three studies in which it wasassessed (RA studies I, III, IV).

In RA study III, most subjects who achieved improvement in physical function and continuedtreatment maintained improvement through Week 520 (120 months) of open-label treatment.

Improvement in quality of life was measured up to Week 156 (36 months) and improvement wasmaintained through that time.

In RA study V, the improvement in the HAQ disability index and the physical component of the

SF-36 showed greater improvement (p < 0.001) for adalimumab/methotrexate combination therapyversus methotrexate monotherapy and adalimumab monotherapy at Week 52, which was maintainedthrough Week 104. Among the 250 subjects who completed the open-label extension study,improvements in physical function were maintained through 10 years of treatment.

Adult plaque psoriasis

The safety and efficacy of adalimumab were studied in adult patients with chronic plaque psoriasis(≥ 10% BSA involvement and PASI ≥ 12 or ≥ 10) who were candidates for systemic therapy orphototherapy in randomised, double-blind studies. 73% of patients enrolled in Psoriasis Studies I and

II had received prior systemic therapy or phototherapy. The safety and efficacy of adalimumab werealso studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant handand/or foot psoriasis who were candidates for systemic therapy in a randomised double-blind study(Psoriasis Study III).

Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A,patients received placebo or adalimumab at an initial dose of 80 mg followed by 40 mg every otherweek starting one week after the initial dose. After 16 weeks of therapy, patients who achieved at leasta PASI 75 response (PASI score improvement of at least 75% relative to baseline), entered period Band received open-label 40 mg adalimumab every other week. Patients who maintained ≥ PASI 75response at Week 33 and were originally randomised to active therapy in Period A, werere-randomised in period C to receive 40 mg adalimumab every other week or placebo for an additional19 weeks. Across all treatment groups, the mean baseline PASI score was 18.9 and the baseline PGAscore ranged from “moderate” (53% of subjects included) to “severe” (41%) to “very severe” (6%).

Psoriasis Study II (CHAMPION) compared the efficacy and safety of adalimumab versusmethotrexate and placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mgand thereafter dose increases up to Week 12, with a maximum dose of 25 mg or an initial dose of80 mg adalimumab followed by 40 mg every other week (starting one week after the initial dose) for16 weeks. There are no data available comparing adalimumab and MTX beyond 16 weeks of therapy.

Patients receiving MTX who achieved a ≥ PASI 50 response at Week 8 and/or 12 did not receivefurther dose increases. Across all treatment groups, the mean baseline PASI score was 19.7 and thebaseline PGA score ranged from “mild” (<1%) to “moderate” (48%) to “severe” (46%) to “verysevere” (6%).

Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into anopen-label extension trial, where adalimumab was given for at least an additional 108 weeks.

In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a

PASI 75 response from baseline at Week 16 (see Tables 12 and 13).

Table 12. Ps study I (REVEAL) efficacy results at 16 weeks

Placebo Adalimumab 40 mg eow

N = 398 N = 814n (%) n (%)≥ PASI 75a 26 (6.5) 578 (70.9)b

Placebo Adalimumab 40 mg eow

N = 398 N = 814n (%) n (%)

PASI 100 3 (0.8) 163 (20.0)b

PGA: Clear/minimal 17 (4.3) 506 (62.2)ba Percent of patients achieving PASI 75 response was calculated as centre-adjusted rateb p < 0.001, adalimumab vs. placebo

Table 13. Ps study II (CHAMPION) efficacy results at 16 weeks

Placebo MTX Adalimumab 40 mg eow

N = 53 N = 110 N = 108n (%) n (%) n (%)≥ PASI 75 10 (18.9) 39 (35.5) 86 (79.6)a,b

PASI 100 1 (1.9) 8 (7.3) 18 (16.7)c,d

PGA: Clear/minimal 6 (11.3) 33 (30.0) 79 (73.1)a,ba p < 0.001 adalimumab vs. placebob p < 0.001 adalimumab vs. methotrexatec p < 0.01 adalimumab vs. placebod p < 0.05 adalimumab vs. methotrexate

In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placeboat Week 33 compared to 5% continuing on adalimumab, p<0.001, experienced “loss of adequateresponse” (PASI score after Week 33 and on or before Week 52 that resulted in a <PASI 50 responserelative to baseline with a minimum of a 6-point increase in PASI score relative to Week 33). Of thepatients who lost adequate response after re-randomisation to placebo who then enrolled into theopen-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and24 weeks of re-treatment, respectively.

A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous adalimumab therapyfor 52 weeks in Psoriasis Study I, and continued adalimumab in the open-label extension trial.

PASI 75 and PGA of clear or minimal response rates in these patients were 74.7% and 59.0%,respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis inwhich all patients who dropped out of the study for adverse events or lack of efficacy, or whodose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response ratesin these patients were 69.6% and 55.7%, respectively, after an additional 108 weeks of open-labeltherapy (total of 160 weeks).

A total of 347 stable responders participated in a withdrawal and retreatment evaluation in anopen-label extension study. During the withdrawal period, symptoms of psoriasis returned over timewith a median time to relapse (decline to PGA “moderate” or worse) of approximately 5 months. Noneof these patients experienced rebound during the withdrawal period. A total of 76.5% (218/285) ofpatients who entered the retreatment period had a response of PGA “clear” or “minimal” after16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1% [123/178]and 88.8% [95/107] for patients who relapsed and who did not relapse during the withdrawal period,respectively). A similar safety profile was observed during retreatment as before withdrawal.

Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I,improvements in the physical and mental component summary scores of the SF-36 were alsosignificant compared to placebo.

In an open-label extension study, for patients who dose escalated from 40 mg every other week to40 mg weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patientsachieved PASI 75 response at Week 12 and 24, respectively.

Psoriasis Study III (REACH) compared the efficacy and safety of adalimumab versus placebo in72 patients with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patientsreceived an initial dose of 80 mg adalimumab followed by 40 mg every other week (starting one weekafter the initial dose) or placebo for 16 weeks. At Week 16, a statistically significantly greaterproportion of patients who received adalimumab achieved PGA of ‘clear’ or ‘almost clear’ for thehands and/or feet compared to patients who received placebo (30.6% versus 4.3%, respectively[P = 0.014]).

Psoriasis Study IV compared efficacy and safety of adalimumab versus placebo in 217 adult patientswith moderate to severe nail psoriasis. Patients received an initial dose of 80 mg adalimumab followedby 40 mg every other week (starting one week after the initial dose) or placebo for 26 weeks followedby open-label adalimumab treatment for an additional 26 weeks. Nail psoriasis assessments includedthe Modified Nail Psoriasis Severity Index (mNAPSI), the Physician’s Global Assessment of

Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 14).

Adalimumab demonstrated a treatment benefit in nail psoriasis patients with different extents of skininvolvement (BSA ≥ 10% (60% of patients) and BSA < 10% and ≥ 5% (40% of patients)).

Table 14. Ps study IV efficacy results at 16, 26 and 52 weeks

Endpoint Week 16 Week 26 Week 52

Placebo-controlled Placebo-controlled Open-label

Placebo Adalimuma Placebo Adalimumab Adalimumab

N = 108 b N = 108 40 mg eow 40 mg eow40 mg eow N = 109 N = 80

N = 109 mNAPSI 75 (%) 2.9 26.0a 3.4 46.6a 65.0

PGA-F 2.9 29.7a 6.9 48.9a 61.3clear/minimal and 2-gradeimprovement (%)

Percent Change in -7.8 -44.2a -11.5 -56.2a -72.2

Total Fingernail

NAPSI (%)a p<0.001, adalimumab vs. placebo

Adalimumab treated patients showed statistically significant improvements at Week 26 compared withplacebo in the DLQI.

Adult hidradenitis suppurativa

The safety and efficacy of adalimumab were assessed in randomised, double-blind, placebo-controlledstudies and an open-label extension study in adult patients with moderate to severe hidradenitissuppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a3-month trial of systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or IIIdisease with at least 3 abscesses or inflammatory nodules.

Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. In Period A, patientsreceived placebo or adalimumab at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mgevery week starting at Week 4 to Week 11. Concomitant antibiotic use was not allowed during thestudy. After 12 weeks of therapy, patients who had received adalimumab in Period A werere-randomised in Period B to 1 of 3 treatment groups (adalimumab 40 mg every week, adalimumab40 mg every other week, or placebo from Week 12 to Week 35). Patients who had been randomised toplacebo in Period A were assigned to receive adalimumab 40 mg every week in Period B.

Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods. In Period A, patientsreceived placebo or adalimumab at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and40 mg every week starting at Week 4 to Week 11. 19.3% of patients had continued baseline oralantibiotic therapy during the study. After 12 weeks of therapy, patients who had received adalimumabin Period A were re-randomised in Period B to 1 of 3 treatment groups (adalimumab 40 mg everyweek, adalimumab 40 mg every other week, or placebo from Week 12 to Week 35). Patients who hadbeen randomised to placebo in Period A were assigned to receive placebo in Period B.

Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extensionstudy in which adalimumab 40 mg was administered every week. Mean exposure in all adalimumabpopulation was 762 days. Throughout all 3 studies patients used topical antiseptic wash daily.

Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas wasassessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in totalabscess and inflammatory nodule count with no increase in abscess count and no increase in drainingfistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric

Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a11 point scale.

At Week 12, a significantly higher proportion of patients treated with adalimumab versus placeboachieved HiSCR. At Week 12, a significantly higher proportion of patients in Study HS-II experienceda clinically relevant decrease in HS-related skin pain (see Table 15). Patients treated with adalimumabhad significantly reduced risk of disease flare during the initial 12 weeks of treatment.

Table 15. Efficacy results at 12 weeks, HS studies I and II

HS study I HS study II

Adalimumab Adalimumab

Placebo 40 mg weekly Placebo 40 mg weekly

Hidradenitis

Suppurativa N = 154 N = 153 N = 163 N = 163

Clinical Response 40 (26.0%) 64 (41.8%)* 45 (27.6%) 96 (58.9%)***(HiSCR)a≥30% Reduction in

N = 109 N = 122 N = 111 N = 105

Skinb 27 (24.8%) 34 (27.9%) 23 (20.7%) 48 (45.7%)***

* P < 0.05, ***P < 0.001, adalimumab versus placeboa Among all randomised patients.b Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating

Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.

Treatment with adalimumab 40 mg every week significantly reduced the risk of worsening ofabscesses and draining fistulas. Approximately twice the proportion of patients in the placebo group inthe first 12 weeks of Studies HS-I and HS-II, compared with those in the adalimumab groupexperienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs13.9%, respectively).

Greater improvements at Week 12 from baseline compared to placebo were demonstrated inskin-specific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI;

Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the

Treatment Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physicalhealth as measured by the physical component summary score of the SF-36 (Study HS-I).

In patients with at least a partial response to adalimumab 40 mg weekly at Week 12, the HiSCR rate at

Week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosingfrequency was reduced to every other week, or in whom treatment was withdrawn (see Table 16).

Table 16. Proportion of patientsa achieving HiSCRb at Weeks 24 and 36 after treatmentreassignment from weekly adalimumab at Week 12

Placebo

Adalimumab 40 mg Adalimumab 40 mg(treatmentevery other week weeklywithdrawal)

N = 70 N = 70

N = 73

Week 24 24 (32.9%) 36 (51.4%) 40 (57.1%)

Week 36 22 (30.1%) 28 (40.0%) 39 (55.7%)a Patients with at least a partial response to adalimumab 40 mg weekly after 12 weeks of treatment.b Patients meeting protocol-specified criteria for loss of response or no improvement were required todiscontinue from the studies and were counted as nonresponders.

Among patients who were at least partial responders at Week 12, and who received continuous weeklyadalimumab therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer termtreatment with adalimumab 40 mg weekly for 96 weeks identified no new safety findings.

Among patients whose adalimumab treatment was withdrawn at Week 12 in Studies HS-I and HS-II,the HiSCR rate 12 weeks after re-introduction of adalimumab 40 mg weekly returned to levels similarto that observed before withdrawal (56.0%).

The safety and efficacy of adalimumab were assessed in over 1,500 patients with moderately toseverely active Crohn’s disease (Crohn’s Disease Activity Index (CDAI) ≥ 220 and ≤ 450) inrandomised, double-blind, placebo-controlled studies. Concomitant stable doses of aminosalicylates,corticosteroids, and/or immunomodulatory agents were permitted and 80% of patients continued toreceive at least one of these medications.

Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies, CD Study I(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naïve patients wererandomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg adalimumab at Week 0and 80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at

Week 2. In CD Study II, 325 patients who had lost response or were intolerant to infliximab wererandomised to receive either 160 mg adalimumab at Week 0 and 80 mg at Week 2 or placebo at Weeks0 and 2. The primary non-responders were excluded from the studies and therefore these patients werenot further evaluated.

Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III,854 patients received open-label 80 mg at Week 0 and 40 mg at Week 2. At Week 4 patients wererandomised to 40 mg every other week, 40 mg every week, or placebo with a total study duration of56 weeks. Patients in clinical response (decrease in CDAI ≥ 70) at Week 4 were stratified and analysedseparately from those not in clinical response at Week 4. Corticosteroid taper was permitted after

Week 8.

CD study I and CD study II induction of remission and response rates are presented in Table 17.

Table 17. Induction of clinical remission and response (percent of patients)

CD Study I: Infliximab naïve patients CD Study II: Infliximabexperienced patients

Placebo Adalimumab Adalimumab Placebo Adalimumab

N = 74 80/40 mg 160/80 mg N = 166 160/80 mg

N = 75 N = 76 N = 159

Week 4

Clinical12% 24% 36%* 7% 21%*remission

CD Study I: Infliximab naïve patients CD Study II: Infliximabexperienced patients

Placebo Adalimumab Adalimumab Placebo Adalimumab

N = 74 80/40 mg 160/80 mg N = 166 160/80 mg

N = 75 N = 76 N = 159

Clinicalresponse 24% 37% 49%** 25% 38%**(CR-100)

All p-values are pairwise comparisons of proportions for adalimumab versus placebo

* p < 0.001

** p < 0.01

Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8and adverse events were more frequently noted in the 160/80 mg group.

In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed inthe primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed toother TNF-antagonists. Maintenance of remission and response rates are presented in Table 18.

Clinical remission results remained relatively constant irrespective of previous TNF-antagonistexposure.

Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumabcompared with placebo at Week 56.

Table 18. Maintenance of clinical remission and response (percent of patients)40 mg Adalimumab 40 mg Adalimumab

Placeboevery other week every week

Week 26 N = 170 N = 172 N = 157

Clinical remission 17% 40%* 47%*

Clinical response (CR-100) 27% 52%* 52%*

Patients in steroid-free 3% (2/66) 19% (11/58)** 15% (11/74)**remission for ≥ 90 daysa

Week 56 N = 170 N = 172 N = 157

Clinical remission 12% 36%* 41%*

Clinical response (CR-100) 17% 41%* 48%*

Patients in steroid-free 5% (3/66) 29% (17/58)* 20% (15/74)**remission for ≥ 90 daysa

* p < 0.001 for adalimumab versus placebo pairwise comparisons of proportions

** p < 0.02 for adalimumab versus placebo pairwise comparisons of proportionsa Of those receiving corticosteroids at baseline

Among patients who were not in response at Week 4, 43% of adalimumab maintenance patientsresponded by Week 12 compared to 30% of placebo maintenance patients. These results suggest thatsome patients who have not responded by Week 4 benefit from continued maintenance therapythrough Week 12. Therapy continued beyond 12 weeks did not result in significantly more responses(see section 4.2).

117/276 patients from CD study I and 272/777 patients from CD studies II and III were followedthrough at least 3 years of open-label adalimumab therapy. 88 and 189 patients, respectively,continued to be in clinical remission. Clinical response (CR-100) was maintained in 102 and233 patients, respectively.

In CD Study I and CD Study II, statistically significant improvement in the disease-specificinflammatory bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patientsrandomised to adalimumab 80/40 mg and 160/80 mg compared to placebo and was seen at

Weeks 26 and 56 in CD Study III as well among the adalimumab treatment groups compared to theplacebo group.

Adult uveitis

The safety and efficacy of adalimumab were assessed in adult patients with non-infectiousintermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in tworandomised, double-masked, placebo-controlled studies (UV I and II). Patients received placebo oradalimumab at an initial dose of 80 mg followed by 40 mg every other week starting one week afterthe initial dose. Concomitant stable doses of one non-biologic immunosuppressant were permitted.

Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oralprednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose ofprednisone 60 mg/day at study entry followed by a mandatory taper schedule, with completecorticosteroid discontinuation by Week 15.

Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment(oral prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwenta mandatory taper schedule, with complete corticosteroid discontinuation by Week 19.

The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure wasdefined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatoryretinal vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best correctedvisual acuity (BCVA).

Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-termextension study with an originally planned duration of 78 weeks. Patients were allowed to continue onstudy medication beyond Week 78 until they had access to adalimumab.

Results from both studies demonstrated statistically significant reduction of the risk of treatmentfailure in patients treated with adalimumab versus patients receiving placebo (see Table 19). Bothstudies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versusplacebo (see Figure 1).

Table 19. Time to treatment failure in studies UV I and UV II

Analysis N Failure Median HRa CI 95% P Valueb

Treatment N (%) time to for HRafailure(months)

Time to treatment failure at or after week 6 in study UV I

Primary analysis (ITT)

Placebo 107 84 (78.5) 3.0 -- -- --

Adalimumab 110 60 (54.5) 5.6 0.50 0.36, 0.70 < 0.001

Time to treatment failure at or after week 2 in study UV II

Primary analysis (ITT)

Placebo 111 61 (55.0) 8.3 -- -- --

Adalimumab 115 45 (39.1) NEc 0.57 0.39, 0.84 0.004

Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted asevent. Drop outs due to reasons other than treatment failure were censored at the time of dropping out.a HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.b 2-sided P value from log rank test.c NE = not estimable. Fewer than half of at-risk subjects had an event.

Figure 1. Kaplan-Meier curves summarizing time to treatment failure on or after Week 6(Study UV I) or Week 2 (Study UV II)

Note: P# = Placebo (Number of Events/Number at Risk); A# = Adalimumab (Number of Events/Number at

Risk).

In Study UV I statistically significant differences in favour of adalimumab versus placebo wereobserved for each component of treatment failure. In Study UV II, statistically significant differenceswere observed for visual acuity only, but the other components were numerically in favour ofadalimumab.

Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II,60 subjects were regarded ineligible (e.g. due to deviations or due to complications secondary todiabetic retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primaryanalysis of efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks ofopen-label adalimumab treatment. Based on the observed data approach, 216 (80.3%) were inquiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with aconcomitant steroid dose ≤ 7.5 mg per day, and 178 (66.2 %) were in steroid-free quiescence. BCVAwas either improved or maintained (< 5 letters deterioration) in 88.6% of the eyes at week 78. Databeyond Week 78 were generally consistent with these results but the number of enrolled subjectsdeclined after this time. Overall, among the patients who discontinued the study, 18% discontinueddue to adverse events, and 8% due to insufficient response to adalimumab treatment.

Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,using the NEI VFQ-25. Adalimumab was numerically favoured for the majority of subscores withstatistically significant mean differences for general vision, ocular pain, near vision, mental health, andtotal score in Study UV I, and for general vision and mental health in Study UV II. Vision relatedeffects were not numerically in favour of adalimumab for colour vision in Study UV I and for colourvision, peripheral vision and near vision in Study UV II.

Anti-adalimumab antibodies may develop during adalimumab treatment. Formation ofanti-adalimumab antibodies is associated with increased clearance and reduced efficacy ofadalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies andthe occurrence of adverse events.

The safety and efficacy of adalimumab was assessed in two studies (pJIA I and II) in children withactive polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onsettypes (most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).

pJIA I

The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind,parallel−group study in 171 children (4-17 years old) with polyarticular JIA. In the open-label lead inphase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated ornon-MTX-treated. Patients who were in the non-MTX stratum were either naïve to or had beenwithdrawn from MTX at least two weeks prior to study drug administration. Patients remained onstable doses of non-steroidal anti-inflammatory drugs (NSAIDs) and or prednisone (≤ 0.2 mg/kg/dayor 10 mg/day maximum). In the OL LI phase all patients received 24 mg/m2 up to a maximum of40 mg adalimumab every other week for 16 weeks. The distribution of patients by age and minimum,median and maximum dose received during the OL LI phase is presented in Table 20.

Table 20. Distribution of patients by age and adalimumab dose received during the OL LI phase

Age group Number of patients at baseline Minimum, median andn (%) maximum dose4 to 7 years 31 (18.1) 10, 20 and 25 mg8 to 12 years 71 (41.5) 20, 25 and 40 mg13 to 17 years 69 (40.4) 25, 40 and 40 mg

Patients demonstrating a Paediatric ACR 30 response at Week 16 were eligible to be randomised intothe double-blind (DB) phase and received either adalimumab 24 mg/m2 up to a maximum of 40 mg, orplacebo every other week for an additional 32 weeks or until disease flare. Disease flare criteria weredefined as a worsening of ≥ 30% from baseline in ≥ 3 of 6 Paediatric ACR core criteria, ≥ 2 activejoints, and improvement of > 30% in no more than 1 of the 6 criteria. After 32 weeks or at diseaseflare, patients were eligible to enrol into the open-label extension phase.

Table 21. Ped ACR 30 responses in the JIA study

Stratum MTX Without MTX

Phase

OL-LI 16 weeks

Ped ACR 30 response 94.1% (80/85) 74.4% (64/86)(n/N)

Efficacy Outcomes

Double-Blind 32 weeks Adalimumab/Placebo/MTX Adalimumab Placebo

MTX (N = 37) (N = 30) (N = 28)(N = 38)

Disease flares at the 36.8% (14/38) 64.9% (24/37)b 43.3% (13/30) 71.4%end of 32 weeksa (20/28)c(n/N)

Median time to > 32 weeks 20 weeks > 32 weeks 14 weeksdisease flarea Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patientsb p = 0.015c p = 0.031

Amongst those who responded at Week 16 (n = 144), the Paediatric ACR 30/50/70/90 responses weremaintained for up to six years in the OLE phase in patients who received adalimumab throughout thestudy. Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline agegroup 13 to 17 years were treated 6 years or longer.

Overall responses were generally better and, fewer patients developed antibodies when treated with thecombination of adalimumab and MTX compared to adalimumab alone. Taking these results intoconsideration, adalimumab is recommended for use in combination with MTX and for use asmonotherapy in patients for whom MTX use is not appropriate (see section 4.2).

pJIA II

The safety and efficacy of adalimumab was assessed in an open-label, multicentre study in 32 children(2 - < 4 years old or aged 4 and above weighing < 15 kg) with moderately to severely activepolyarticular JIA. The patients received 24 mg/m2 body surface area (BSA) of adalimumab up to amaximum of 20 mg every other week as a single dose via SC injection for at least 24 weeks. Duringthe study, most subjects used concomitant MTX, with fewer reporting use of corticosteroids or

NSAIDs.

At Week 12 and Week 24, PedACR 30 response was 93.5% and 90.0%, respectively, using theobserved data approach. The proportions of subjects with PedACR 50/70/90 at Week 12 and Week 24were 90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded(Paediatric ACR 30) at Week 24 (n = 27 out of 30 patients), the Paediatric ACR 30 responses weremaintained for up to 60 weeks in the OLE phase in patients who received adalimumab throughout thistime period. Overall, 20 subjects were treated for 60 weeks or longer.

The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind studyin 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. Patients wererandomised to receive either 24 mg/m2 body surface area (BSA) of adalimumab up to a maximum of40 mg, or placebo every other week for 12 weeks. The double-blind period is followed by anopen-label (OL) period during which patients received 24 mg/m2 BSA of adalimumab up to amaximum of 40 mg every other week subcutaneously for up to an additional 192 weeks. The primaryendpoint was the percent change from Baseline to Week 12 in the number of active joints with arthritis(swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which wasachieved with mean percent decrease of -62.6% (median percent change -88.9%) in patients in theadalimumab group compared to -11.6% (median percent change -50.0%) in patients in the placebogroup. Improvement in number of active joints with arthritis was maintained during the OL periodthrough Week 156 for the 26 of 31 (84%) patients in the adalimumab group who remained in thestudy. Although not statistically significant, the majority of patients demonstrated clinicalimprovement in secondary endpoints such as number of sites of enthesitis, tender joint count (TJC),swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 response.

The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a

Physician’s Global Assessment (PGA) ≥ 4 or > 20% BSA involvement or > 10% BSA involvementwith very thick lesions or Psoriasis Area and Severity Index (PASI) ≥ 20 or ≥ 10 with clinicallyrelevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topicaltherapy and heliotherapy or phototherapy.

Patients received adalimumab 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), ormethotrexate 0.1 - 0.4 mg/kg weekly (up to 25 mg). At Week 16, more patients randomised toadalimumab 0.8 mg/kg had positive efficacy responses (e.g. PASI 75) than those randomised to0.4 mg/kg eow or MTX.

Table 22. Paediatric plaque psoriasis efficacy results at 16 weeks

MTXa Adalimumab 0.8 mg/kg eow

N = 37 N = 38

PASI 75b 12 (32.4%) 22 (57.9%)

PGA: Clear/minimalc 15 (40.5%) 23 (60.5%)a MTX = methotrexateb P = 0.027, adalimumab 0.8 mg/kg versus MTXc P = 0.083, adalimumab 0.8 mg/kg versus MTX

Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to36 weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades).

Patients were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and responserates observed during retreatment were similar to the previous double-blind period: PASI 75 responseof 78.9% (15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).

In the open-label period of the study, PASI 75 and PGA clear or minimal responses were maintainedfor up to an additional 52 weeks with no new safety findings.

Adolescent hidradenitis suppurativa

There are no clinical trials with adalimumab in adolescent patients with HS. Efficacy of adalimumabfor the treatment of adolescent patients with HS is predicted based on the demonstrated efficacy andexposure-response relationship in adult HS patients and the likelihood that the disease course,pathophysiology, and drug effects are substantially similar to that of adults at the same exposurelevels. Safety of the recommended adalimumab dose in the adolescent HS population is based oncross-indication safety profile of adalimumab in both adults and paediatric patients at similar or morefrequent doses (see section 5.2).

Adalimumab was assessed in a multicentre, randomised, double-blind clinical trial designed toevaluate the efficacy and safety of induction and maintenance treatment with doses dependent on bodyweight (< 40 kg or ≥ 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years,with moderate to severe Crohn’s disease (CD) defined as Paediatric Crohn’s Disease Activity Index(PCDAI) score > 30. Subjects had to have failed conventional therapy (including a corticosteroidand/or an immunomodulator) for CD. Subjects may also have previously lost response or beenintolerant to infliximab.

All subjects received open-label induction therapy at a dose based on their Baseline body weight:

160 mg at Week 0 and 80 mg at Week 2 for subjects ≥ 40 kg, and 80 mg and 40 mg, respectively, forsubjects < 40 kg.

At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low

Dose or Standard Dose maintenance regimens as shown in Table 23.

Table 23. Maintenance regimen

Patient weight Low dose Standard dose< 40 kg 10 mg eow 20 mg eow≥ 40 kg 20 mg eow 40 mg eow

The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score ≤ 10.

Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 pointsfrom Baseline) rates are presented in Table 24. Rates of discontinuation of corticosteroids orimmunomodulators are presented in Table 25.

Table 24. Paediatric CD study − PCDAI clinical remission and response

Standard Dose Low Dose P value*40/20 mg eow 20/10 mg eow

N = 93 N = 95

Week 26

Clinical remission 38.7% 28.4% 0.075

Clinical response 59.1% 48.4% 0.073

Week 52

Clinical remission 33.3% 23.2% 0.100

Clinical response 41.9% 28.4% 0.038

* p value for Standard Dose versus Low Dose comparison.

Table 25. Paediatric CD study − discontinuation of corticosteroids or immunomodulators andfistula remission

Standard Dose Low Dose P value140/20 mg eow 20/10 mg eow

Discontinued corticosteroids N = 33 N = 38

Week 26 84.8% 65.8% 0.066

Week 52 69.7% 60.5% 0.420

Discontinuation of immunomodulators2 N = 60 N = 57

Week 52 30.0% 29.8% 0.983

Fistula remission3 N = 15 N = 21

Week 26 46.7% 38.1% 0.608

Week 52 40.0% 23.8% 0.3031 p value for Standard Dose versus Low Dose comparison.2 Immunosuppressant therapy could only be discontinued at or after Week 26 at the investigator’s discretionif the subject met the clinical response criterion3 defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive post-Baselinevisits

Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass

Index and height velocity were observed for both treatment groups.

Statistically and clinically significant improvements from Baseline were also observed in bothtreatment groups for quality of life parameters (including IMPACT III).

One hundred patients (n = 100) from the Paediatric CD Study continued in an open-label long-termextension study. After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining inthe study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be inclinical response per PCDAI.

The safety and efficacy of adalimumab was assessed in a multicenter, randomised, double-blind, trialin 93 paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayoscore 6 to 12 with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) whohad an inadequate response or intolerance to conventional therapy. Approximately 16% of patients inthe study had failed prior anti-TNF treatment. Patients who received corticosteroids at enrollment wereallowed to taper their corticosteroid therapy after Week 4.

In the induction period of the study, 77 patients were randomised 3:2 to receive double-blind treatmentwith adalimumab at an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and1.2 mg/kg (maximum of 80 mg) at Week 2; or an induction dose of 2.4 mg/kg (maximum of 160 mg)at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2. Both groups received0.6 mg/kg (maximum of 40 mg) at Week 4 and Week 6. Following an amendment to the study design,the remaining 16 patients who enrolled in the induction period received open-label treatment withadalimumab at the induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and1.2 mg/kg (maximum of 80 mg) at Week 2.

At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as adecrease in PMS ≥ 2 points and ≥ 30% from Baseline) were randomised equally to receivedouble-blind maintenance treatment with adalimumab at a dose of 0.6 mg/kg (maximum of 40 mg)every week (ew), or a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week (eow).

Prior to an amendment to the study design, 12 additional patients who demonstrated clinical responseper PMS were randomised to receive placebo but were not included in the confirmatory analysis ofefficacy.

Disease flare was defined as an increase in PMS of at least 3 points (for patients with PMS of 0 to 2 at

Week 8), at least 2 points (for patients with PMS of 3 to 4 at Week 8), or at least 1 point (for patientswith PMS of 5 to 6 at Week 8).

Patients who met criteria for disease flare at or after Week 12 were randomised to receive are-induction dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg)and continued to receive their respective maintenance dose regimen afterwards.

The co-primary endpoints of the study were clinical remission per PMS (defined as PMS ≤ 2 and noindividual subscore > 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a

Mayo Score ≤ 2 and no individual subscore > 1) at Week 52 in patients who achieved clinical responseper PMS at Week 8.

Clinical remission rates per PMS at Week 8 for patients in each of the adalimumab double-blindinduction groups are presented in Table 26.

Table 26. Clinical remission per PMS at 8 weeks

Adalimumaba Adalimumabb,c

Maximum of 160 mg at Maximum of 160 mg at

Week 0/Placebo at Week 1 Week 0 and Week 1

N = 30 N = 47

Clinical remission 13/30 (43.3%) 28/47 (59.6%)a Adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 mg/kg (maximumof 80 mg) at Week 2b Adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of80 mg) at Week 2c Not including open-label Induction dose of adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0 and

Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2

Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and Week 6

Note 2: Patients with missing values at Week 8 were considered as not having met the endpoint

At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined asa decrease in Mayo Score ≥ 3 points and ≥ 30% from Baseline) in Week 8 responders, mucosal healing(defined as Mayo endoscopy subscore ≤ 1) in Week 8 responders, clinical remission per FMS in

Week 8 remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8responders were assessed in patients who received adalimumab at the double-blind maximum 40 mgeow (0.6 mg/kg) and maximum 40 mg ew (0.6 mg/kg) maintenance doses (Table 27).

Table 27. Efficacy results at 52 weeks

Adalimumaba Adalimumabb

Maximum of 40 mg eow Maximum of 40 mg ew

N = 31 N = 31

Clinical remission in Week 8 9/31 (29.0%) 14/31 (45.2%)

PMS responders

Clinical response in Week 8 19/31 (61.3%) 21/31 (67.7%)

PMS responders

Mucosal healing in Week 8 12/31 (38.7%) 16/31 (51.6%)

PMS responders

Clinical remission in Week 8 9/21 (42.9%) 10/22 (45.5%)

PMS remitters

Corticosteroid-free remission in 4/13 (30.8%) 5/16 (31.3%)

Week 8 PMS respondersca Adalimumab 0.6 mg/kg (maximum of 40 mg) every other weekb Adalimumab 0.6 mg/kg (maximum of 40 mg) every weekc In patients receiving concomitant corticosteroids at baseline

Note: Patients with missing values at Week 52 or who were randomised to receive re-induction or maintenancetreatment were considered non-responders for Week 52 endpoints

Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative

Colitis Activity Index (PUCAI) (defined as a decrease in PUCAI ≥ 20 points from Baseline) andclinical remission per PUCAI (defined as PUCAI < 10) at Week 8 and Week 52 (Table 28).

Table 28. Exploratory endpoints results per PUCAI

Week 8

Adalimumaba Adalimumabb,c

Maximum of 160 mg at Maximum of 160 mg at

Week 0/Placebo at Week 1 Week 0 and Week 1

N = 30 N = 47

Clinical remission per PUCAI 10/30 (33.3%) 22/47 (46.8%)

Clinical response per PUCAI 15/30 (50.0%) 32/47 (68.1%)

Week 52

Adalimumabd Adalimumabe

Maximum of 40 mg eow Maximum of 40 mg ew

N = 31 N = 31

Clinical remission per PUCAI 14/31 (45.2%) 18/31 (58.1%)in Week 8 PMS responders

Clinical response per PUCAI in 18/31 (58.1%) 16/31 (51.6%)

Week 8 PMS respondersa Adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of80 mg) at Week 2b Adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg)at Week 2c Not including open-label Induction dose of adalimumab 2.4 mg/kg (maximum of 160 mg) at Week 0 and

Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2d Adalimumab 0.6 mg/kg (maximum of 40 mg) every other weeke Adalimumab 0.6 mg/kg (maximum of 40 mg) every week

Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and Week 6

Note 2: Patients with missing values at Week 8 were considered as not having met the endpoints

Note 3: Patients with missing values at Week 52 or who were randomised to receive re-induction or maintenancetreatment were considered non-responders for Week 52 endpoints

Of the adalimumab-treated patients who received re-induction treatment during the maintenanceperiod, 2/6 (33%) achieved clinical response per FMS at Week 52.

Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver

Work Productivity and Activity Impairment (WPAI) scores for the groups treated with adalimumab.

Clinically meaningful increases (improvement) from Baseline in height velocity were observed for thegroups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in

Body Mass Index were observed for subjects on the high maintenance dose of maximum 40 mg(0.6 mg/kg) ew.

Paediatric uveitis

The safety and efficacy of adalimumab was assessed in a randomised, double-masked, controlled studyof 90 paediatric patients from 2 to < 18 years of age with active JIA-associated non-infectious anterioruveitis who were refractory to at least 12 weeks of methotrexate treatment. Patients received eitherplacebo or 20 mg adalimumab (if < 30 kg) or 40 mg adalimumab (if ≥ 30 kg) every other week incombination with their baseline dose of methotrexate.

The primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure wereworsening or sustained non-improvement in ocular inflammation, partial improvement withdevelopment of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitteduse of concomitant medications, and suspension of treatment for an extended period of time.

Adalimumab significantly delayed the time to treatment failure, as compared to placebo (see Figure 2,

P < 0.0001 from log rank test). The median time to treatment failure was 24.1 weeks for subjectstreated with placebo, whereas the median time to treatment failure was not estimable for subjectstreated with adalimumab because less than one-half of these subjects experienced treatment failure.

Adalimumab significantly decreased the risk of treatment failure by 75% relative to placebo, as shownby the hazard ratio (HR = 0.25 [95% CI: 0.12, 0.49]).

Figure 2. Kaplan-Meier curves summarizing time to treatment failure in the paediatric uveitisstudy

Note: P = Placebo (Number at Risk); H = Adalimumab (Number at Risk).

Following the administration of 24 mg/m2 (maximum of 40 mg) subcutaneously every other week topatients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean troughsteady-state (values measured from Week 20 to 48) serum adalimumab concentration was5.6 ± 5.6 µg/ml (102% CV) for adalimumab without concomitant methotrexate and 10.9 ± 5.2 µg/ml(47.7% CV) with concomitant methotrexate.

In patients with polyarticular JIA who were 2 to <4 years old or aged 4 and above weighing < 15 kgdosed with adalimumab 24 mg/m2, the mean trough steady-state serum adalimumab concentrationswas 6.0 ± 6.1 µg/ml (101% CV) for adalimumab without concomitant methotrexate and7.9 ± 5.6 µg/ml (71.2% CV) with concomitant methotrexate.

Following the administration of 24 mg/m2 (maximum of 40 mg) subcutaneously every other week topatients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (valuesmeasured at Week 24) serum adalimumab concentrations were 8.8 ± 6.6 μg/ml for adalimumabwithout concomitant methotrexate and 11.8 ± 4.3 μg/ml with concomitant methotrexate.

Following the administration of 0.8 mg/kg (maximum of 40 mg) subcutaneously every other week topaediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab troughconcentration was approximately 7.4 ± 5.8 µg/ml (79% CV).

Adalimumab exposure in adolescent HS patients was predicted using population pharmacokineticmodelling and simulation based on cross-indication pharmacokinetics in other paediatric patients(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-relatedarthritis). The recommended adolescent HS dosing schedule is 40 mg every other week. Sinceexposure to adalimumab can be affected by body size, adolescents with higher body weight andinadequate response may benefit from receiving the recommended adult dose of 40 mg every week.

In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.

At Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose(20/10 mg eow) maintenance treatment groups based on their body weight. The mean (±SD) serumadalimumab trough concentrations achieved at Week 4 were 15.7 ± 6.6 µg/ml for patients ≥ 40 kg(160/80 mg) and 10.6 ± 6.1 µg/ml for patients < 40 kg (80/40 mg).

For patients who stayed on their randomised therapy, the mean (±SD) adalimumab troughconcentrations at Week 52 were 9.5 ± 5.6 µg/ml for the Standard Dose group and 3.5 ± 2.2 µg/ml forthe Low Dose group. The mean trough concentrations were maintained in patients who continued toreceive adalimumab treatment eow for 52 weeks. For patients who dose escalated from eow to weeklyregimen, the mean (±SD) serum concentrations of adalimumab at Week 52 were 15.3 ± 11.4 μg/ml(40/20 mg, weekly) and 6.7 ± 3.5 μg/ml (20/10 mg, weekly).

Following the subcutaneous administration of body weight-based dosing of 0.6 mg/kg (maximum of40 mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-stateserum adalimumab concentration was 5.01 ± 3.28 μg/ml at Week 52. For patients who received0.6 mg/kg (maximum of 40 mg) every week, the mean (±SD) trough steady-state serum adalimumabconcentration was 15.7 ± 5.60 μg/ml at Week 52.

Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokineticmodelling and simulation based on cross-indication pharmacokinetics in other paediatric patients(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-relatedarthritis). No clinical exposure data are available on the use of a loading dose in children < 6 years.

The predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to aninitial increase in systemic exposure.

Exposure-response relationship in paediatric population

On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-responserelationship was established between plasma concentrations and PedACR 50 response. The apparentadalimumab plasma concentration that produces half the maximum probability of PedACR 50response (EC50) was 3 μg/ml (95% CI: 1-6 μg/ml).

Exposure-response relationships between adalimumab concentration and efficacy in paediatric patientswith severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal,respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumabconcentrations, both with a similar apparent EC50 of approximately 4.5 μg/ml (95% CI 0.4-47.6 and1.9-10.5, respectively).

After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumabwas slow, with peak serum concentrations being reached about 5 days after administration. Theaverage absolute bioavailability of adalimumab estimated from three studies following a single 40 mgsubcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg,concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11to 15 ml/hour, the distribution volume (Vss) ranged from 5 to 6 litres and the mean terminal phasehalf-life was approximately two weeks. Adalimumab concentrations in the synovial fluid from severalrheumatoid arthritis patients ranged from 31-96% of those in serum.

Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoidarthritis (RA) patients the mean steady-state trough concentrations were approximately 5 µg/ml(without concomitant methotrexate) and 8 to 9 µg/ml (with concomitant methotrexate), respectively.

The serum adalimumab trough levels at steady-state increased roughly proportionally with dosefollowing 20, 40 and 80 mg subcutaneous dosing every other week and every week.

In adult patients with psoriasis, the mean steady-state trough concentration was 5 μg/ml duringadalimumab 40 mg every other week monotherapy treatment.

In adult patients with hidradenitis suppurativa, a dose of 160 mg adalimumab on Week 0 followed by80 mg on Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 μg/ml at

Week 2 and Week 4. The mean steady-state trough concentration at Week 12 through Week 36 wereapproximately 8 to 10 μg/ml during adalimumab 40 mg every week treatment.

In patients with Crohn’s disease, the loading dose of 80 mg adalimumab on Week 0 followed by40 mg adalimumab on Week 2 achieves serum adalimumab trough concentrations of approximately5.5 μg/ml during the induction period. A loading dose of 160 mg adalimumab on Week 0 followed by80 mg adalimumab on Week 2 achieves serum adalimumab trough concentrations of approximately12 μg/ml during the induction period. Mean steady-state trough levels of approximately 7 μg/ml wereobserved in Crohn’s disease patients who received a maintenance dose of 40 mg adalimumab everyother week.

In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mgadalimumab every other week starting at Week 1, resulted in mean steady-state concentrations ofapproximately 8 to 10 μg/ml.

Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulationpredicted comparable adalimumab exposure and efficacy in patients treated with 80 mg every otherweek when compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps,patients with adolescent HS, and paediatric patients ≥ 40 kg with CD and UC).

Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend towardhigher apparent clearance of adalimumab with increasing body weight. After adjustment for weightdifferences, gender and age appeared to have a minimal effect on adalimumab clearance. The serumlevels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lowerin patients with measurable AAA.

Hepatic or renal impairment

Adalimumab has not been studied in patients with hepatic or renal impairment.

Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity,repeated dose toxicity, and genotoxicity.

An embryo-foetal developmental toxicity/perinatal developmental study has been performed incynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence ofharm to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment offertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate modelsfor an antibody with limited cross-reactivity to rodent TNF and to the development of neutralisingantibodies in rodents.

L-Histidine

L-Histidine hydrochloride monohydrate

Sucrose

Edetate Disodium Dihydrate

L-Methionine

Polysorbate 80

Water for injections

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinalproducts.

3 years

Store in a refrigerator (2°C -8°C). Do not freeze. Keep the vial in the outer carton in order to protectfrom light.

A single Amsparity vial may be stored at temperatures up to a maximum of 30°C for a period of upto 30 days. The vial must be protected from light, and discarded if not used within the 30-dayperiod.

Amsparity 40 mg solution for injection in single-use vial (type I glass), fitted with rubber stoppers,aluminium crimps and flip-off seals.

1 Pack of 2 boxes each containing:

1 vial (0.8 ml sterile solution), 1 empty sterile injection syringe, 1 needle, 1 vial adapter and 2 alcoholpads.

Any unused medicinal product or waste material should be disposed of in accordance with localrequirements.

Pfizer Europe MA EEIG

Boulevard de la Plaine 171050 Bruxelles

Belgium

EU/1/19/1415/002

Date of first authorisation: 13 February 2020

Date of latest renewal: 19 September 2024

Detailed information on this medicinal product is available on the website of the European

Medicines Agency https://www.ema.europa.eu.